Grant ID DP240117
Awarded On November 15, 2023
Title A Novel High Throughput Platform for Drug Screening Against Dormant and Migrating High-Grade Glioma Cells
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization Single Cell Biotechnology Inc
Principal Investigator/Program Director Digant Dave
Cancer Sites Breast, Head and Neck, Lung and Bronchus
Contracted Amount $2,536,132*

*Pending contract negotiation

Lay Summary

Glioblastoma (GBM) affects nearly 12,000 adults in the U.S. per year and, despite efforts over 3 decades, the median survival is unchanged at 14-18 months and 5-year survival at 6%. Emerging evidence supports two cell populations, migrating and dormant cells, that are difficult to identify and promote tumor recurrence and mortality in GBM. Current methods of drug discovery only focus on rapid cell growth and most drugs developed for GBM do not target dormant and migrating cells that are responsible for recurrence, metastasis, and ultimately patient mortality. There is a lack of methods for identification, retrieval, and analysis of these cancer cells. Without such a platform, there is no way...

Read More